Back to News
Market Impact: 0.2
AbbVie Seeks EMA Nod For SKYRIZI Subcutaneous Induction In Crohn's Disease
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
AbbVie filed a regulatory application with the European Medicines Agency (EMA) for SKYRIZI subcutaneous induction therapy in adults with moderately to severely active Crohn’s disease. The filing supports potential label expansion in Europe, though no approval timeline or financial impact was provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
ABBV0.25
More News
- How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?
- Simply Injectables RI Welcomes Susan McKenna, NP, as Aesthetic Injector and GLP-1 Program Lead
- Musk says Terrafab chip factory could outperform rivals despite challenges
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Will Warner Bros. kill Skydance — or will David Ellison kill Warner Bros?
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Software for Buy-Side Teams: Build the Research Stack
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit